There were 5 New Hires and Promotions in the #BioHealthCapitalRegion in the month of August! Check out all the #PeopleOnTheMove Here Facility Logix LLC Ceres Nanosciences, Inc. Vaccitech CRB

Veralox specializes in developing drugs to address unmet medical needs. It is currently working on therapies to target type 1 diabetes and a medication-induced immune disorder.

Healthcare giant Johnson & Johnson today announced the six winners of the Champions of Science Africa Innovation Challenge 2.0 at the 28th World Economic Forum on Africa in Cape Town.

The winning teams will get share of $300 000 prize pool, along with extensive mentoring and network building to support the expansion and sustainability of the companies and their programmes.

Microsoft Corp. is teaming up with U.K. drugmaker AstraZeneca Plc on creating a health-tech incubator in Paris aimed at bringing new solutions to the field’s most difficult problems.

M. Javad Aman, PhD, President and CEO of Integrated BioTherapeutics, explains how his Montgomery County company is focused on discovery research for the development of new vaccines and therapies to fight emerging infectious diseases.

College Park, Maryland, will serve as a SBIR Road Tour stop for the state of Maryland, and will provide attendees with an opportunity to hear directly from the participating federal agency program managers that administer over 5,000 new awards annually. Register today for a one-on-one appointment with your choice of agencies!

The SBIR Road Tour is a national outreach effort connecting entrepreneurs working on advanced technologies to the country’s largest source of early stage funding – the SBIR/STTR programs. Also known as America’s Seed Fund, the SBIR/STTR programs provide over $3 billion in funding to small businesses each year in a wide variety of technology areas.

Forbes released its annual list of the country's most innovative leaders, comprising 100 founders and CEOs known for encouraging creative and highly successful innovation at their organizations.

Johns Hopkins University is launching a new center for psychedelic research that will use psychedelic drugs to study the mind and therapies for diseases like addiction.

Machfu, an industrial Internet of Things technology company, announced today that it has been awarded the Small Business Innovation Research (SBIR) Phase II extension grant for $1 million by the U.S. Department of Energy (DOE). Machfu won the Phase II award in 2017.

Vensana Capital—an independent, medtech-focused venture capital investment firm supported by Versant Ventures—has launched with a $225 million fund and ambitions to support new breakthroughs in medical devices, diagnostics and data science.

Organizers of the $150K "Make Your Medical Device Pitch for Kids!" competition today announced the 12 finalists who are advancing to the live pitch component of the competition scheduled for Sept. 22 during the 7th Annual Pediatric Device Innovation Symposium hosted by Children's National Health System. The pitch competition, sponsored by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI), focuses on Neonatal Intensive Care Unit (NICU) innovations, a pediatric subspecialty that the Food and Drug Administration (FDA) identifies as having a significant unmet need for medical devices.

Making a therapeutic that contains biological components is just the start of creating a medicine. Then, biopharmaceutical companies must capture that drug and ensure that it’s free of contamination. New techniques and technologies can accomplish that capture and cleanup more simply and economically.

Bristol-Myers Squibb has allied with biotech accelerator BioMotiv. The deal sets Bristol-Myers up to found and fund biotechs with BioMotiv before going on to acquire them outright once a preclinical candidate is identified. 

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today announced an option and license agreement for exclusive worldwide rights to Clearside's proprietary, in-office SCS Microinjector™ for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other conditions for which anti-vascular endothelial growth factor (anti-VEGF) treatment is currently the standard of care. REGENXBIO plans to evaluate RGX-314 using Clearside's SCS Microinjector for in-office, non-surgical delivery into the suprachoroidal space, while continuing to advance its RGX-314 subretinal delivery program currently in development for wet AMD and DR.

Low interest rates and high stock valuations are fueling U.S. life sciences CEOs’ growing appetite for mergers and acquisitions, KPMG’s CEO Outlook found.

It’s a pivotal moment for the MedImmune spinout, which has put the fate of its first prospective product in regulators' hands.

Biotech is booming across the country, especially in the top biotech clusters like Boston, San Francisco, New York and in the BioHealth Capital Region (BHCR). The global biotechnology market is expected to reach $775.2 billion by 2024 at a compound annual growth rate of 9.9 percent. 

Boosted by new research and development positions, Massachusetts last year experienced the fastest rate of biopharma job growth in a decade, according to a report released Tuesday from state trade group MassBio.

The agreement is intended to create a system for children with rare and complex health conditions.

In support of the U.S. government’s policy to maintain a stockpile to be able to protect every American from smallpox, Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $2 billion over 10 years for the continued supply of ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (SNS). The actual number of ACAM2000 doses to be procured is dependent on certain timing and tiered-pricing terms that are subject to the discretion of ASPR. ACAM2000 vaccine is the only vaccine licensed by the

With multiple brand new spec lab/ office suites and numerous shared amenities, 704 Quince Orchard promises to be the 'best in class' lab building in the I-270 Corridor.

The Maryland Industrial Partnerships program and the Maryland Technology Development Corp. will jointly host a free briefing about how faculty and local businesses can participate in funding programs at Frostburg State University on Sept. 11 at 2 p.m. in the Harold J. Cordts Physical Education Center Hall of Fame Room.

In the past several years, Greater Boston has cemented itself as the global epicenter of life sciences research. According to JLL’s Life Sciences Outlook report, the region consistently ranks in the top tier of U.S. life sciences clusters, with only San Francisco as its main adversary.

AstraZeneca PLC spinout Viela Bio Inc. filed for an IPO of up to $150 million.

Cambridge, U.K.-based AstraZeneca said in February 2018 that its research and development unit, MedImmune LLC, would move out six experimental compounds from its early-stage inflammation and autoimmunity programs to form Viela Bio, an independent biotech company.

The company hasn't yet disclosed its share price or date for an initial public offering.

This group of young professionals was chosen from a pool of nearly 500 nominations.

Good job Arti Santhanam, John Gustin and Silvia Goncalves!

Calling all entrepreneurs and Innovators in the DMV area… Have you heard? JLABS @ Washington DC is coming to the District! In anticipation of our upcoming launch we are hosting a community mixer.  This is a wonderful opportunity for those looking to expand your network, connect with other entrepreneurs, VCs, academics and industry leaders. You’ll get an chance to meet the local JLABS Team, learn about future programming and how to become a resident.

Here are seven pieces of wisdom and advice about the role of innovation in healthcare that executives from hospitals and health systems across the country shared with Becker's Hospital Review in August:

Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for inebilizumab, an investigational anti-CD19 monoclonal antibody, for the treatment of patients with neuromyelitis optica spectrum disorder (NMOSD) — a rare autoimmune disease characterized by unpredictable attacks that often lead to severe, irreparable disability including blindness and paralysis.

Sonavex, Inc., a privately held medical device company focused on empowered patient care, announced that it received a $3 million Phase IIB Small Business Innovation Research (SBIR) grant from the National Institutes of Health to use its EchoMark & EchoSure devices to support arteriovenous (AV) fistula maturation and long-term viability. The award provides capital for prospective clinical studies and continued research and development efforts.

OCTOBER 8-10, 2019 | NATIONAL HARBOR, MD

DELIVERING INNOVATION ACCELERATING COMMERCIALIZATION

Join leadership from America's seed fund, representing over $3.5B of early-state, high-risk technology funding for small business.

A University of Maryland (UMD) team has been awarded a $1 million grant by the National Science Foundation’s Integrative Strategies for Understanding Neural and Cognitive Systems (NCS) program to investigate the complex effects of intestinal serotonin on both gut and brain health. The project, “Developing engineering solutions to investigate microbiome-to-neuron communication,” aims to provide a more realistic picture of the complex gut-microbiome-brain axis system (GMBA).

These are the Baltimore Business Journal's 2019 40 Under 40 honorees 

This group of young professionals was chosen from a pool of nearly 500 nominations.

The move comes as Sands continues to expand its investing approach.